Tag Archives: project
#431733 Why Humanoid Robots Are Still So Hard to ...
Picture a robot. In all likelihood, you just pictured a sleek metallic or chrome-white humanoid. Yet the vast majority of robots in the world around us are nothing like this; instead, they’re specialized for specific tasks. Our cultural conception of what robots are dates back to the coining of the term robots in the Czech play, Rossum’s Universal Robots, which originally envisioned them as essentially synthetic humans.
The vision of a humanoid robot is tantalizing. There are constant efforts to create something that looks like the robots of science fiction. Recently, an old competitor in this field returned with a new model: Toyota has released what they call the T-HR3. As humanoid robots go, it appears to be pretty dexterous and have a decent grip, with a number of degrees of freedom making the movements pleasantly human.
This humanoid robot operates mostly via a remote-controlled system that allows the user to control the robot’s limbs by exerting different amounts of pressure on a framework. A VR headset completes the picture, allowing the user to control the robot’s body and teleoperate the machine. There’s no word on a price tag, but one imagines a machine with a control system this complicated won’t exactly be on your Christmas list, unless you’re a billionaire.
Toyota is no stranger to robotics. They released a series of “Partner Robots” that had a bizarre affinity for instrument-playing but weren’t often seen doing much else. Given that they didn’t seem to have much capability beyond the automaton that Leonardo da Vinci made hundreds of years ago, they promptly vanished. If, as the name suggests, the T-HR3 is a sequel to these robots, which came out shortly after ASIMO back in 2003, it’s substantially better.
Slightly less humanoid (and perhaps the more useful for it), Toyota’s HSR-2 is a robot base on wheels with a simple mechanical arm. It brings to mind earlier machines produced by dream-factory startup Willow Garage like the PR-2. The idea of an affordable robot that could simply move around on wheels and pick up and fetch objects, and didn’t harbor too-lofty ambitions to do anything else, was quite successful.
So much so that when Robocup, the international robotics competition, looked for a platform for their robot-butler competition @Home, they chose HSR-2 for its ability to handle objects. HSR-2 has been deployed in trial runs to care for the elderly and injured, but has yet to be widely adopted for these purposes five years after its initial release. It’s telling that arguably the most successful multi-purpose humanoid robot isn’t really humanoid at all—and it’s curious that Toyota now seems to want to return to a more humanoid model a decade after they gave up on the project.
What’s unclear, as is often the case with humanoid robots, is what, precisely, the T-HR3 is actually for. The teleoperation gets around the complex problem of control by simply having the machine controlled remotely by a human. That human then handles all the sensory perception, decision-making, planning, and manipulation; essentially, the hardest problems in robotics.
There may not be a great deal of autonomy for the T-HR3, but by sacrificing autonomy, you drastically cut down the uses of the robot. Since it can’t act alone, you need a convincing scenario where you need a teleoperated humanoid robot that’s less precise and vastly more expensive than just getting a person to do the same job. Perhaps someday more autonomy will be developed for the robot, and the master maneuvering system that allows humans to control it will only be used in emergencies to control the robot if it gets stuck.
Toyota’s press release says it is “a platform with capabilities that can safely assist humans in a variety of settings, such as the home, medical facilities, construction sites, disaster-stricken areas and even outer space.” In reality, it’s difficult to see such a robot being affordable or even that useful in the home or in medical facilities (unless it’s substantially stronger than humans). Equally, it certainly doesn’t seem robust enough to be deployed in disaster zones or outer space. These tasks have been mooted for robots for a very long time and few have proved up to the challenge.
Toyota’s third generation humanoid robot, the T-HR3. Image Credit: Toyota
Instead, the robot seems designed to work alongside humans. Its design, standing 1.5 meters tall, weighing 75 kilograms, and possessing 32 degrees of freedom in its body, suggests it is built to closely mimic a person, rather than a robot like ATLAS which is robust enough that you can imagine it being useful in a war zone. In this case, it might be closer to the model of the collaborative robots or co-bots developed by Rethink Robotics, whose tons of safety features, including force-sensitive feedback for the user, reduce the risk of terrible PR surrounding killer robots.
Instead the emphasis is on graceful precision engineering: in the promo video, the robot can be seen balancing on one leg before showing off a few poised, yoga-like poses. This perhaps suggests that an application in elderly care, which Toyota has ventured into before and which was the stated aim of their simple HSR-2, might be more likely than deployment to a disaster zone.
The reason humanoid robots remain so elusive and so tempting is probably because of a simple cognitive mistake. We make two bad assumptions. First, we assume that if you build a humanoid robot, give its joints enough flexibility, throw in a little AI and perhaps some pre-programmed behaviors, then presto, it will be able to do everything humans can. When you see a robot that moves well and looks humanoid, it seems like the hardest part is done; surely this robot could do anything. The reality is never so simple.
We also make the reverse assumption: we assume that when we are finally replaced, it will be by perfect replicas of our own bodies and brains that can fulfill all the functions we used to fulfill. Perhaps, in reality, the future of robots and AI is more like its present: piecemeal, with specialized algorithms and specialized machines gradually learning to outperform humans at every conceivable task without ever looking convincingly human.
It may well be that the T-HR3 is angling towards this concept of machine learning as a platform for future research. Rather than trying to program an omni-capable robot out of the box, it will gradually learn from its human controllers. In this way, you could see the platform being used to explore the limits of what humans can teach robots to do simply by having them mimic sequences of our bodies’ motion, in the same way the exploitation of neural networks is testing the limits of training algorithms on data. No one machine will be able to perform everything a human can, but collectively, they will vastly outperform us at anything you’d want one to do.
So when you see a new android like Toyota’s, feel free to marvel at its technical abilities and indulge in the speculation about whether it’s a PR gimmick or a revolutionary step forward along the road to human replacement. Just remember that, human-level bots or not, we’re already strolling down that road.
Image Credit: Toyota Continue reading
Posted in Human Robots
#431653 9 Robot Animals Built From Nature’s ...
Millions of years of evolution have allowed animals to develop some elegant and highly efficient solutions to problems like locomotion, flight, and dexterity. As Boston Dynamics unveils its latest mechanical animals, here’s a rundown of nine recent robots that borrow from nature and why.
SpotMini – Boston Dynamics
Starting with BigDog in 2005, the US company has built a whole stable of four-legged robots in recent years. Their first product was designed to be a robotic packhorse for soldiers that borrowed the quadrupedal locomotion of animals to travel over terrain too rough for conventional vehicles.
The US Army ultimately rejected the robot for being too noisy, according to the Guardian, but since then the company has scaled down its design, first to the Spot, then a first edition of the SpotMini that came out last year.
The latter came with a robotic arm where its head should be and was touted as a domestic helper, but a sleeker second edition without the arm was released earlier this month. There’s little detail on what the new robot is designed for, but the more polished design suggests a more consumer-focused purpose.
OctopusGripper – Festo
Festo has released a long line of animal-inspired machines over the years, from a mechanical kangaroo to robotic butterflies. Its latest creation isn’t a full animal—instead it’s a gripper based on an octopus tentacle that can be attached to the end of a robotic arm.
The pneumatically-powered device is made of soft silicone and features two rows of suction cups on its inner edge. By applying compressed air the tentacle can wrap around a wide variety of differently shaped objects, just like its natural counterpart, and a vacuum can be applied to the larger suction cups to grip the object securely. Because it’s soft, it holds promise for robots required to operate safely in collaboration with humans.
CRAM – University of California, Berkeley
Cockroaches are renowned for their hardiness and ability to disappear down cracks that seem far too small for them. Researchers at UC Berkeley decided these capabilities could be useful for search and rescue missions and so set about experimenting on the insects to find out their secrets.
They found the bugs can squeeze into gaps a fifth of their normal standing height by splaying their legs out to the side without significantly slowing themselves down. So they built a palm-sized robot with a jointed plastic shell that could do the same to squeeze into crevices half its normal height.
Snake Robot – Carnegie Mellon University
Search and rescue missions are a common theme for animal-inspired robots, but the snake robot built by CMU researchers is one of the first to be tested in a real disaster.
A team of roboticists from the university helped Mexican Red Cross workers search collapsed buildings for survivors after the 7.1-magnitude earthquake that struck Mexico City in September. The snake design provides a small diameter and the ability to move in almost any direction, which makes the robot ideal for accessing tight spaces, though the team was unable to locate any survivors.
The snake currently features a camera on the front, but researchers told IEEE Spectrum that the experience helped them realize they should also add a microphone to listen for people trapped under the rubble.
Bio-Hybrid Stingray – Harvard University
Taking more than just inspiration from the animal kingdom, a group from Harvard built a robotic stingray out of silicone and rat heart muscle cells.
The robot uses the same synchronized undulations along the edge of its fins to propel itself as a ray does. But while a ray has two sets of muscles to pull the fins up and down, the new device has only one that pulls them down, with a springy gold skeleton that pulls them back up again. The cells are also genetically modified to be activated by flashes of light.
The project’s leader eventually hopes to engineer a human heart, and both his stingray and an earlier jellyfish bio-robot are primarily aimed at better understanding how that organ works.
Bat Bot – Caltech
Most recent advances in drone technology have come from quadcopters, but Caltech engineers think rigid devices with rapidly spinning propellers are probably not ideal for use in close quarters with humans.
That’s why they turned to soft-winged bats for inspiration. That’s no easy feat, though, considering bats use more than 40 joints with each flap of their wings, so the team had to optimize down to nine joints to avoid it becoming too bulky. The simplified bat can’t ascend yet, but its onboard computer and sensors let it autonomously carry out glides, turns, and dives.
Salto – UC Berkeley
While even the most advanced robots tend to plod around, tree-dwelling animals have the ability to spring from branch to branch to clear obstacles and climb quickly. This could prove invaluable for search and rescue robots by allowing them to quickly traverse disordered rubble.
UC Berkeley engineers turned to the Senegal bush baby for inspiration after determining it scored highest in “vertical jumping agility”—a combination of how high and how frequently an animal can jump. They recreated its ability to get into a super-low crouch that stores energy in its tendons to create a robot that could carry out parkour-style double jumps off walls to quickly gain height.
Pleurobot – École Polytechnique Fédérale de Lausanne
Normally robots are masters of air, land, or sea, but the robotic salamander built by researchers at EPFL can both walk and swim.
Its designers used X-ray videos to carefully study how the amphibians move before using this to build a true-to-life robotic version using 3D printed bones, motorized joints, and a synthetic nervous system made up of electronic circuitry.
The robot’s low center of mass and segmented legs make it great at navigating rough terrain without losing balance, and the ability to swim gives added versatility. They also hope it will help paleontologists gain a better understanding of the movements of the first tetrapods to transition from water to land, which salamanders are the best living analog of.
Eelume – Eelume
A snakelike body isn’t only useful on land—eels are living proof it’s an efficient way to travel underwater, too. Norwegian robotics company Eelume has borrowed these principles to build a robot capable of sub-sea inspection, maintenance, and repair.
The modular design allows operators to put together their own favored configuration of joints and payloads such as sensors and tools. And while an early version of the robot used the same method of locomotion as an eel, the latest version undergoing sea trials has added a variety of thrusters for greater speeds and more maneuverability.
Image Credit: Boston Dynamics / YouTube Continue reading
Posted in Human Robots
#431559 Drug Discovery AI to Scour a Universe of ...
On a dark night, away from city lights, the stars of the Milky Way can seem uncountable. Yet from any given location no more than 4,500 are visible to the naked eye. Meanwhile, our galaxy has 100–400 billion stars, and there are even more galaxies in the universe.
The numbers of the night sky are humbling. And they give us a deep perspective…on drugs.
Yes, this includes wow-the-stars-are-freaking-amazing-tonight drugs, but also the kinds of drugs that make us well again when we’re sick. The number of possible organic compounds with “drug-like” properties dwarfs the number of stars in the universe by over 30 orders of magnitude.
Next to this multiverse of possibility, the chemical configurations scientists have made into actual medicines are like the smattering of stars you’d glimpse downtown.
But for good reason.
Exploring all that potential drug-space is as humanly impossible as exploring all of physical space, and even if we could, most of what we’d find wouldn’t fit our purposes. Still, the idea that wonder drugs must surely lurk amid the multitudes is too tantalizing to ignore.
Which is why, Alex Zhavoronkov said at Singularity University’s Exponential Medicine in San Diego last week, we should use artificial intelligence to do more of the legwork and speed discovery. This, he said, could be one of the next big medical applications for AI.
Dogs, Diagnosis, and Drugs
Zhavoronkov is CEO of Insilico Medicine and CSO of the Biogerontology Research Foundation. Insilico is one of a number of AI startups aiming to accelerate drug discovery with AI.
In recent years, Zhavoronkov said, the now-famous machine learning technique, deep learning, has made progress on a number of fronts. Algorithms that can teach themselves to play games—like DeepMind’s AlphaGo Zero or Carnegie Mellon’s poker playing AI—are perhaps the most headline-grabbing of the bunch. But pattern recognition was the thing that kicked deep learning into overdrive early on, when machine learning algorithms went from struggling to tell dogs and cats apart to outperforming their peers and then their makers in quick succession.
[Watch this video for an AI update from Neil Jacobstein, chair of Artificial Intelligence and Robotics at Singularity University.]
In medicine, deep learning algorithms trained on databases of medical images can spot life-threatening disease with equal or greater accuracy than human professionals. There’s even speculation that AI, if we learn to trust it, could be invaluable in diagnosing disease. And, as Zhavoronkov noted, with more applications and a longer track record that trust is coming.
“Tesla is already putting cars on the street,” Zhavoronkov said. “Three-year, four-year-old technology is already carrying passengers from point A to point B, at 100 miles an hour, and one mistake and you’re dead. But people are trusting their lives to this technology.”
“So, why don’t we do it in pharma?”
Trial and Error and Try Again
AI wouldn’t drive the car in pharmaceutical research. It’d be an assistant that, when paired with a chemist or two, could fast-track discovery by screening more possibilities for better candidates.
There’s plenty of room to make things more efficient, according to Zhavoronkov.
Drug discovery is arduous and expensive. Chemists sift tens of thousands of candidate compounds for the most promising to synthesize. Of these, a handful will go on to further research, fewer will make it to human clinical trials, and a fraction of those will be approved.
The whole process can take many years and cost hundreds of millions of dollars.
This is a big data problem if ever there was one, and deep learning thrives on big data. Early applications have shown their worth unearthing subtle patterns in huge training databases. Although drug-makers already use software to sift compounds, such software requires explicit rules written by chemists. AI’s allure is its ability to learn and improve on its own.
“There are two strategies for AI-driven innovation in pharma to ensure you get better molecules and much faster approvals,” Zhavoronkov said. “One is looking for the needle in the haystack, and another one is creating a new needle.”
To find the needle in the haystack, algorithms are trained on large databases of molecules. Then they go looking for molecules with attractive properties. But creating a new needle? That’s a possibility enabled by the generative adversarial networks Zhavoronkov specializes in.
Such algorithms pit two neural networks against each other. One generates meaningful output while the other judges whether this output is true or false, Zhavoronkov said. Together, the networks generate new objects like text, images, or in this case, molecular structures.
“We started employing this particular technology to make deep neural networks imagine new molecules, to make it perfect right from the start. So, to come up with really perfect needles,” Zhavoronkov said. “[You] can essentially go to this [generative adversarial network] and ask it to create molecules that inhibit protein X at concentration Y, with the highest viability, specific characteristics, and minimal side effects.”
Zhavoronkov believes AI can find or fabricate more needles from the array of molecular possibilities, freeing human chemists to focus on synthesizing only the most promising. If it works, he hopes we can increase hits, minimize misses, and generally speed the process up.
Proof’s in the Pudding
Insilico isn’t alone on its drug-discovery quest, nor is it a brand new area of interest.
Last year, a Harvard group published a paper on an AI that similarly suggests drug candidates. The software trained on 250,000 drug-like molecules and used its experience to generate new molecules that blended existing drugs and made suggestions based on desired properties.
An MIT Technology Review article on the subject highlighted a few of the challenges such systems may still face. The results returned aren’t always meaningful or easy to synthesize in the lab, and the quality of these results, as always, is only as good as the data dined upon.
Stanford chemistry professor and Andreesen Horowitz partner, Vijay Pande, said that images, speech, and text—three of the areas deep learning’s made quick strides in—have better, cleaner data. Chemical data, on the other hand, is still being optimized for deep learning. Also, while there are public databases, much data still lives behind closed doors at private companies.
To overcome the challenges and prove their worth, Zhavoronkov said, his company is very focused on validating the tech. But this year, skepticism in the pharmaceutical industry seems to be easing into interest and investment.
AI drug discovery startup Exscientia inked a deal with Sanofi for $280 million and GlaxoSmithKline for $42 million. Insilico is also partnering with GlaxoSmithKline, and Numerate is working with Takeda Pharmaceutical. Even Google may jump in. According to an article in Nature outlining the field, the firm’s deep learning project, Google Brain, is growing its biosciences team, and industry watchers wouldn’t be surprised to see them target drug discovery.
With AI and the hardware running it advancing rapidly, the greatest potential may yet be ahead. Perhaps, one day, all 1060 molecules in drug-space will be at our disposal. “You should take all the data you have, build n new models, and search as much of that 1060 as possible” before every decision you make, Brandon Allgood, CTO at Numerate, told Nature.
Today’s projects need to live up to their promises, of course, but Zhavoronkov believes AI will have a big impact in the coming years, and now’s the time to integrate it. “If you are working for a pharma company, and you’re still thinking, ‘Okay, where is the proof?’ Once there is a proof, and once you can see it to believe it—it’s going to be too late,” he said.
Image Credit: Klavdiya Krinichnaya / Shutterstock.com Continue reading
Posted in Human Robots
#431427 Why the Best Healthcare Hacks Are the ...
Technology has the potential to solve some of our most intractable healthcare problems. In fact, it’s already doing so, with inventions getting us closer to a medical Tricorder, and progress toward 3D printed organs, and AIs that can do point-of-care diagnosis.
No doubt these applications of cutting-edge tech will continue to push the needle on progress in medicine, diagnosis, and treatment. But what if some of the healthcare hacks we need most aren’t high-tech at all?
According to Dr. Darshak Sanghavi, this is exactly the case. In a talk at Singularity University’s Exponential Medicine last week, Sanghavi told the audience, “We often think in extremely complex ways, but I think a lot of the improvements in health at scale can be done in an analog way.”
Sanghavi is the chief medical officer and senior vice president of translation at OptumLabs, and was previously director of preventive and population health at the Center for Medicare and Medicaid Innovation, where he oversaw the development of large pilot programs aimed at improving healthcare costs and quality.
“How can we improve health at scale, not for only a small number of people, but for entire populations?” Sanghavi asked. With programs that benefit a small group of people, he explained, what tends to happen is that the average health of a population improves, but the disparities across the group worsen.
“My mantra became, ‘The denominator is everybody,’” he said. He shared details of some low-tech but crucial fixes he believes could vastly benefit the US healthcare system.
1. Regulatory Hacking
Healthcare regulations are ultimately what drive many aspects of patient care, for better or worse. Worse because the mind-boggling complexity of regulations (exhibit A: the Affordable Care Act is reportedly about 20,000 pages long) can make it hard for people to get the care they need at a cost they can afford, but better because, as Sanghavi explained, tweaking these regulations in the right way can result in across-the-board improvements in a given population’s health.
An adjustment to Medicare hospitalization rules makes for a relevant example. The code was updated to state that if people who left the hospital were re-admitted within 30 days, that hospital had to pay a penalty. The result was hospitals taking more care to ensure patients were released not only in good health, but also with a solid understanding of what they had to do to take care of themselves going forward. “Here, arguably the writing of a few lines of regulatory code resulted in a remarkable decrease in 30-day re-admissions, and the savings of several billion dollars,” Sanghavi said.
2. Long-Term Focus
It’s easy to focus on healthcare hacks that have immediate, visible results—but what about fixes whose benefits take years to manifest? How can we motivate hospitals, regulators, and doctors to take action when they know they won’t see changes anytime soon?
“I call this the reality TV problem,” Sanghavi said. “Reality shows don’t really care about who’s the most talented recording artist—they care about getting the most viewers. That is exactly how we think about health care.”
Sanghavi’s team wanted to address this problem for heart attacks. They found they could reliably determine someone’s 10-year risk of having a heart attack based on a simple risk profile. Rather than monitoring patients’ cholesterol, blood pressure, weight, and other individual factors, the team took the average 10-year risk across entire provider panels, then made providers responsible for controlling those populations.
“Every percentage point you lower that risk, by hook or by crook, you get some people to stop smoking, you get some people on cholesterol medication. It’s patient-centered decision-making, and the provider then makes money. This is the world’s first predictive analytic model, at scale, that’s actually being paid for at scale,” he said.
3. Aligned Incentives
If hospitals are held accountable for the health of the communities they’re based in, those hospitals need to have the right incentives to follow through. “Hospitals have to spend money on community benefit, but linking that benefit to a meaningful population health metric can catalyze significant improvements,” Sanghavi said.
Darshak Sanghavi speaking at Singularity University’s 2017 Exponential Medicine Summit in San Diego, CA.
He used smoking cessation as an example. His team designed a program where hospitals were given a score (determined by the Centers for Disease Control and Prevention) based on the smoking rate in the counties where they’re located, then given monetary incentives to improve their score. Improving their score, in turn, resulted in better health for their communities, which meant fewer patients to treat for smoking-related health problems.
4. Social Determinants of Health
Social determinants of health include factors like housing, income, family, and food security. The answer to getting people to pay attention to these factors at scale, and creating aligned incentives, Sanghavi said, is “Very simple. We just have to measure it to start with, and measure it universally.”
His team was behind a $157 million pilot program called Accountable Health Communities that went live this year. The program requires all Medicare and Medicaid beneficiaries get screened for various social determinants of health. With all that data being collected, analysts can pinpoint local trends, then target funds to address the underlying problem, whether it’s job training, drug use, or nutritional education. “You’re then free to invest the dollars where they’re needed…this is how we can improve health at scale, with very simple changes in the incentive structures that are created,” he said.
5. ‘Securitizing’ Public Health
Sanghavi’s final point tied back to his discussion of aligning incentives. As misguided as it may seem, the reality is that financial incentives can make a huge difference in healthcare outcomes, from both a patient and a provider perspective.
Sanghavi’s team did an experiment in which they created outcome benchmarks for three major health problems that exist across geographically diverse areas: smoking, adolescent pregnancy, and binge drinking. The team proposed measuring the baseline of these issues then creating what they called a social impact bond. If communities were able to lower their frequency of these conditions by a given percent within a stated period of time, they’d get paid for it.
“What that did was essentially say, ‘you have a buyer for this outcome if you can achieve it,’” Sanghavi said. “And you can try to get there in any way you like.” The program is currently in CMS clearance.
AI and Robots Not Required
Using robots to perform surgery and artificial intelligence to diagnose disease will undoubtedly benefit doctors and patients around the US and the world. But Sanghavi’s talk made it clear that our healthcare system needs much more than this, and that improving population health on a large scale is really a low-tech project—one involving more regulatory and financial innovation than technological innovation.
“The things that get measured are the things that get changed,” he said. “If we choose the right outcomes to predict long-term benefit, and we pay for those outcomes, that’s the way to make progress.”
Image Credit: Wonderful Nature / Shutterstock.com Continue reading
Posted in Human Robots